$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Health / Medical Research

FDA Removes Breyanzi Limitation For CNS Lymphoma Patients

The update lets the CAR T-cell therapy reach lymphoma in the brain and spine. Its new safety data come from a cohort of five patients.

TML Health DeskNov 22, 8:26 AM ET · 1 min read
Cell culture flasks in a laboratory at Porton Down. CAR T-cell therapies are built from a patient's own cells in facilities like this one. Photo: Defence Images / Crown Copyright, via Flickr.
Summary

A five-patient cohort moved a federal label, and the label now reaches the patients CAR T trials spent years excluding.

Tap a passage. React to the part that matters.

The FDA has removed the label limitation that kept Breyanzi from patients whose lymphoma involves the central nervous system.

The November 2026 prescribing information deletes the limitation of use that excluded primary and secondary central nervous system lymphoma from the therapy's large B-cell lymphoma indications. It doesn't create a standalone indication for CNS lymphoma, and patients still qualify through the lymphoma label and its prior-treatment rules.

The safety case rests on a very small cohort. Study 6, a single-arm study coded JCAR017-BCM-001, treated five patients with relapsed or refractory primary CNS lymphoma. Cytokine release syndrome appeared in 60 percent of them, three of five, with no case at grade 3 or higher.

Neurologic toxicities appeared in 40 percent, two of five, with onset between 3 and 8 days and duration between 7 and 22 days. The events included seizure, headache, encephalopathy, and paresis. Five patients can show that a therapy isn't immediately prohibitive in this population, and they can't size the risk with any precision.

The therapy underneath the change is established. Liso-cel is a CD19-directed CAR T-cell therapy made from a patient's own cells, cleared for large B-cell lymphoma subtypes that include diffuse large B-cell, high-grade, primary mediastinal, and follicular lymphoma grade 3B. In the TRANSFORM trial its median event-free survival ran 10.1 months against 2.3 months on standard therapy.

Breyanzi is the second CAR T-cell therapy to clear this barrier. The FDA removed the same limitation from axicabtagene ciloleucel, sold as Yescarta, in February 2026. Breyanzi's boxed warnings stay in place, covering cytokine release syndrome, neurologic toxicities, and secondary blood cancers.

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.